You are here: Industry Insights > Pfizer

News List

Pfizer Issues Recall for 2 Lots of RELPAX americanpharmaceuticalreview
August 19, 2019
Pfizer is voluntarily recalling RELPAX® (eletriptan hydrobromide) 40 mg tablets, lots AR5407 and CD4565, to the Patient level. Pfizer Inc. initiated this recall because these product lots may not meet Pfizer’s in-house microbiological specification for ..
Pfizer recalls migraine med Relpax because of bacterial contamination fiercepharma
August 18, 2019
After an earlier recall of Relpax, Pfizer is again tracking down a couple of lots of the migraine headache med.
GSK completes transaction with Pfizer to form new world-leading Consumer Healthcare Joint Venture worldpharmanews
August 07, 2019
The Joint Venture brings together two highly complementary portfolios of trusted consumer health brands, including GSK's Sensodyne...
Mylan and Upjohn Join Forces contractpharma
August 05, 2019
Creates new global pharma company; revenues expected in the $20bn range.
GSK completes transaction with Pfizer to form new Consumer Healthcare Joint Venture biospectrumasia
August 04, 2019
The Joint Venture brings together two highly complementary portfolios of consumer health brands, including GSK’s Sensodyne, Voltaren and Panadol and Pfizer’s Advil, Centrum and Caltrate
GSK closes consumer healthcare JV transaction with Pfizer pharmaceutical-technology
August 02, 2019
GlaxoSmithKline (GSK) has closed the transaction related to the formation of a consumer healthcare joint venture (JV) with Pfizer, with the new company to operate as GSK Consumer Healthcare.
Pfizer, GlaxoSmithKline Announce Joint Venture americanpharmaceuticalreview
August 02, 2019
Pfizer announced the closing of its joint venture with GlaxoSmithKline to combine the parties’ respective consumer healthcare businesses to create the world’s largest over-the-counter (OTC) business.
Chasing Pfizer and J&J, Bayer’s Nubeqa nabs fast FDA nod in prostate cancer biospectrumasia
August 01, 2019
Pfizer and Astellas’ Xtandi and Johnson & Johnson’s Erleada may have big head starts in the prostate cancer market, but Bayer and partner Orion have a new entry—and they're looking to carve out a share.
Mylan to merge with Pfizer’s off-patent drugs unit Upjohn pharmaceutical-technology
July 31, 2019
Mylan has signed a definitive agreement to combine with Pfizer’s off-patent branded and generic medicines division Upjohn to form a new pharmaceutical company.
Pfizer's big split is finally here, thanks to a giant generics merger with Mylan biospectrumasia
July 30, 2019
Looks like consumer health isn’t the only franchise Pfizer is looking to shed. In a payoff for years of split-up talk, the pharma giant's got hive-off plans for its generics business, too.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 83 84 Next page